This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

The Effectiveness of St. John’s Wort in Major Depressive Disorder: A Naturalistic Phase 2 Follow-Up in Which Nonresponders Were Provided Alternate Medication

Alan J. Gelenberg, MD; Richard C. Shelton, MD; Paul Crits-Christoph, PhD; Martin B. Keller, MD; David L. Dunner, MD; Robert M. A. Hirschfeld, MD; Michael E. Thase, MD; James M. Russell, MD; R. Bruce Lydiard, PhD, MD; Robert J. Gallop, PhD; Linda Todd, BA; David J. Hellerstein, MD; Paul J. Goodnick, MD; Gabor I. Keitner, MD; Stephen M. Stahl, MD, PhD; Uriel Halbreich, MD; and Heather S. Hopkins, MA

Published: August 1, 2004

Article Abstract

Background: A continuation study of an extract of St. John’s wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John’s wort extract and placebo.

Method: Seventeen subjects with DSM-IV-defined major depressive disorder who responded to St. John’s wort extract in the acute-phase study (phase 1) were continued on double-blind treatment with the same preparation for 24 weeks. Ninety-five subjects who did not respond to either St. John’s wort or placebo were treated with an antidepressant for 24 weeks.

Results: During antidepressant treatment, mean scores on the Hamilton Rating Scale for Depression for phase 1 nonresponders decreased significantly (p < .0001), with no significant difference between St. John’s wort nonresponders and placebo nonresponders. Of the 17 subjects continued on treatment with St. John’s wort extract, 5 (29.4%) relapsed.

Conclusions: The subjects who did not respond to St. John’s wort extract or placebo in phase 1 were, by and large, not resistant to antidepressant treatment. This suggests that the lack of efficacy found by Shelton et al. in the acute-phase study was unlikely to be the result of a high proportion of treatment-resistant subjects.

Volume: 65

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived...

Read More...